GLP terminology: visual evidence map
This diagram is a simplified research map, not a mechanism-of-action claim for research-use material. Use it to orient the evidence category before reading citations.
Email info@researchchem.co and our team will help with your order.
GLP-1 and GLP-2 are established glucagon-like peptide terms. “GLP-3” is not a recognized human peptide category; it is an informal label sometimes applied to triple-agonist research such as retatrutide.
This diagram is a simplified research map, not a mechanism-of-action claim for research-use material. Use it to orient the evidence category before reading citations.
GLP-1 and GLP-2 are established glucagon-like peptide terms. “GLP-3” is not a recognized human peptide category; it is an informal label sometimes applied to triple-agonist research such as retatrutide.
GLP-1 is an established incretin hormone; semaglutide, tirzepatide, retatrutide, and related compounds are distinguished by the receptors they activate.
GLP-2 is glucagon-like peptide-2, a distinct 33-amino-acid peptide associated mainly with intestinal biology.
“GLP-3” is a scientifically inaccurate informal label. Retatrutide is more precisely described as a triple agonist that activates GIP, GLP-1, and glucagon receptors.
GLP-1 and GLP-2 are established scientific terms, but they describe different peptides and biological roles. They are not numbered generations of the same product category.
“GLP-3” is not a formal human peptide classification. It is sometimes used informally for triple-agonist research, including retatrutide, whose receptor targets are GIP, GLP-1, and glucagon.
GLP-1 means glucagon-like peptide-1. Research on this pathway includes GLP-1 receptor agonism and broader incretin biology.
That does not mean every GLP-related compound is the same. Semaglutide is generally discussed as a GLP-1 receptor agonist, tirzepatide as a dual GIP/GLP-1 receptor agonist, and retatrutide as a triple hormone receptor agonist involving GIP, GLP-1, and glucagon receptors.
Formally, GLP-2 means glucagon-like peptide-2, a 33-amino-acid proglucagon-derived peptide mainly associated with intestinal biology. That is separate from the internet habit of calling second-generation dual-incretin products GLP-2.
Some informal comparisons use GLP-2 to mean a two-pathway product, but that conflicts with the established peptide name. Tirzepatide is more precisely described by its dual GIP and GLP-1 receptor activity.
Lilly describes “GLP-3” as a scientifically inaccurate informal label for triple hormone receptor agonists. The term does not identify a recognized human peptide category.
Retatrutide is more precisely described as a triple agonist because one molecule activates GIP, GLP-1, and glucagon receptors.
GLP-1 is an established incretin term. GLP-2 is a different, formally recognized peptide. “GLP-3” is informal shorthand rather than an official human peptide label.
When comparing research products, use the exact compound name, receptor targets, available size, and product-specific research note. Research Chem Co products are offered only for laboratory research use.
“GLP-3” is an informal and scientifically inaccurate label sometimes applied to triple-agonist research such as retatrutide. It is not a formal human GLP peptide category.
No. Tirzepatide is described as a dual GIP and GLP-1 receptor agonist. GLP-2 is a separate glucagon-like peptide with its own established biological meaning.
Formal GLP-2 means glucagon-like peptide-2, a proglucagon-derived intestinal peptide. It is not the same thing as the two-receptor shorthand people sometimes use online.
Start with the semaglutide, tirzepatide, and retatrutide research notes, then compare the current product pages for product details, strength options, pricing, and subscription savings.
No. Research Chem Co products are sold strictly for laboratory research use only and are not intended for human consumption, diagnosis, treatment, or prevention of disease.
GLP-1 and GLP-2 synthesized and released from intestinal endocrine cells · PMC review
NCBI MeSH definition for glucagon-like peptide-2 · NCBI MeSH
Lilly explanation of retatrutide and GLP-3 terminology · Eli Lilly
Retatrutide phase 2 obesity study · New England Journal of Medicine, 2023
Buying guides
Batch documentation
Document sets vary by manufacturer and product. Start by matching the product, lot or sample identifiers, dates, methods, results, and release status.
Read the guideReading the COA
COA layouts vary, but the core review is consistent: identify the issuer and material, match the lot or sample, read the named methods and results, and check…
Read the guideCategory boundaries
Research-use laboratory products are not prescription drugs or compounded medicines. Compounded drugs follow separate federal and state pathways and are prep…
Read the guide